Cutler Group LP Tricida, Inc. Transaction History

Cutler Group LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 07, 2023	SELL	$0.14 - $12.49 $994 - $88,679	-7,100 Reduced 77.17%	2,100 $0
Q3 2022 Oct 25, 2022	BUY	$8.51 - $13.6 $48,507 - $77,520	5,700 Added 162.86%	9,200 $96,000
Q2 2022 Aug 04, 2022	SELL	$7.31 - $11.85 $4,568 - $7,406	-625 Reduced 15.15%	3,500 $33,000
Q4 2020 Jan 21, 2021	SELL	$4.37 - $9.46 $7,429 - $16,082	-1,700 Reduced 29.18%	4,125 $29,000
Q3 2020 Oct 27, 2020	BUY	$8.56 - $26.93 $49,862 - $156,867	5,825 New	5,825 $52,000

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.